Literature DB >> 9792027

[Biometrical principles in medicine].

M Löffler1.   

Abstract

Mesh:

Year:  1998        PMID: 9792027     DOI: 10.1007/bf03042670

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


× No keyword cloud information.
  6 in total

1.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.

Authors:  R I Fisher; E R Gaynor; S Dahlberg; M M Oken; T M Grogan; E M Mize; J H Glick; C A Coltman; T P Miller
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

2.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

Authors: 
Journal:  N Engl J Med       Date:  1988-12-29       Impact factor: 91.245

3.  Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone.

Authors:  E Dühmke; V Diehl; M Loeffler; R P Mueller; U Ruehl; N Willich; A Georgii; S Roth; D Matthaei; S Sehlen; O Brosteanu; D Hasenclever; R Wilkowski; K Becker
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-09-01       Impact factor: 7.038

Review 4.  Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

Authors:  D Hasenclever; M Loeffler; V Diehl
Journal:  Ann Oncol       Date:  1996       Impact factor: 32.976

5.  Randomized versus historical controls for clinical trials.

Authors:  H Sacks; T C Chalmers; H Smith
Journal:  Am J Med       Date:  1982-02       Impact factor: 4.965

Review 6.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.